Synergic fabrication of arsenic and anticancer drug-loaded ZIF-8 nanocomposites for improved radiofrequency ablation of liver metastasis cancer therapy

References

• Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5):S5–14. doi: 10.1053/j.gastro.2004.09.011
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochimica Et Biophysica Acta (BBA) - Rev can. 2020;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Investig. 2013;123(5):1911–1918. doi: 10.1172/JCI66024
   PubMed Web of Science ®Google Scholar
• Dhar D, Baglieri J, Kisseleva T, et al. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med. 2020;245(2):96–108. doi: 10.1177/1535370219898141
   PubMed Web of Science ®Google Scholar
• Bruix J, Han K-H, Gores G, et al. Liver cancer: approaching a personalized care. J Hepatol. 2015;62(1):S144–S156. doi: 10.1016/j.jhep.2015.02.007
   PubMedGoogle Scholar
• Kumar CS, Raja MD, Sundar DS, et al. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydr Polym. 2015;128:63–74. doi: 10.1016/j.carbpol.2015.04.010
   PubMed Web of Science ®Google Scholar
• Xia Q, Li L, Zhao L. Silica nanoparticle‑based dual‑responsive nanoprodrug system for liver cancer therapy. Exp Ther Med. 2017;14(3):2071–2077. doi: 10.3892/etm.2017.4768
   PubMed Web of Science ®Google Scholar
• Ashokan AP, Paulpandi M, Dinesh D, et al. Toxicity on dengue mosquito vectors through myristica fragrans-synthesized zinc oxide nanorods, and their cytotoxic effects on liver cancer cells (HepG2). J Clust Sci. 2017;28(1):205–226. doi: 10.1007/s10876-016-1075-y
   Web of Science ®Google Scholar
• Lee MH, Kim E-J, Lee H, et al. Liposomal texaphyrin theranostics for metastatic liver cancer. J Am Chem Soc. 2016;138:16380–16387. doi: 10.1021/jacs.6b09713
   PubMed Web of Science ®Google Scholar
• Liu P, Xu S, Zhang M, et al. Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. Metallomics. 2013;5(7):871–878. doi: 10.1039/C3MT20272K
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang T, Sun W, et al. Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma. Free Radic Biol Med. 2017;106:24–37. doi: 10.1016/j.freeradbiomed.2017.02.015
   PubMed Web of Science ®Google Scholar
• Xin J, Zhang K, Huang J, et al. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy. Biomater Sci. 2019;7(1):262–271. doi: 10.1039/C8BM01039K
   Web of Science ®Google Scholar
• Yuan T, Zhang H, Chen B, et al. Association between lung cancer risk and inorganic arsenic concentration in drinking water: a dose–response meta-analysis. Toxicol Res. 2018;7(6):1257–1266. doi: 10.1039/C8TX00177D
   Web of Science ®Google Scholar
• Adil M, Kandhare AD, Ghosh P, et al. Sodium arsenite-induced myocardial bruise in rats: Ameliorative effect of naringin via TGF-β/Smad and Nrf/HO pathways. Chem Biol Interact. 2016;253:66–77. doi: 10.1016/j.cbi.2016.05.015
   PubMed Web of Science ®Google Scholar
• Adil M, Kandhare AD, Visnagri A, et al. Naringin ameliorates sodium arsenite-induced renal and hepatic toxicity in rats: decisive role of KIM-1, Caspase-3, TGF-β, and TNF-α. Ren Fail. 2015;37(8):1396–1407. doi: 10.3109/0886022X.2015.1074462
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Cheng S-C, Wahner Hendrickson AE, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(7):957–968. doi: 10.1016/S1470-2045(20)30180-7
   PubMed Web of Science ®Google Scholar
• Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012;11(12):2644–2653. doi: 10.1158/1535-7163.MCT-12-0447
   PubMed Web of Science ®Google Scholar
• Soni N, Soni N, Pandey H, et al. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci. 2016;481:107–116. doi: 10.1016/j.jcis.2016.07.020
   PubMed Web of Science ®Google Scholar
• Habib S, Singh M. Recent advances in lipid-based nanosystems for gemcitabine and gemcitabine–combination therapy. Nanomaterials. 2021;11(3):597. doi: 10.3390/nano11030597
   Web of Science ®Google Scholar
• Zhang Y, Kim WY, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials. 2013;34(13):3447–3458. doi: 10.1016/j.biomaterials.2013.01.063
   PubMed Web of Science ®Google Scholar
• Thompson BR, Shi J, Zhu H-J, et al. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice. Biochem Pharmacol. 2020;180:114127. doi: 10.1016/j.bcp.2020.114127
   PubMed Web of Science ®Google Scholar
• Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology. 2001;60(1):8–18. doi: 10.1159/000055290
   PubMed Web of Science ®Google Scholar
• Xie H, Liu X, Huang Z, et al. Nanoscale zeolitic imidazolate framework (ZIF)–8 in cancer theranostics: current challenges and prospects. Current Challen Prosp Can. 2022;14(16):3935. doi: 10.3390/cancers14163935
   Google Scholar
• Abdelhamid HN. Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review. Curr Med Chem. 2021;28(34):7023–7075. doi: 10.2174/0929867328666210608143703
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun Y, Li S, et al. Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy. RSC Adv. 2020;10(62):37600–37620. doi: 10.1039/D0RA07950B
   PubMed Web of Science ®Google Scholar
• Vasconcelos IB, da Silva TG, Militão GCG, et al. Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8. RSC Adv. 2012;2(25):9437–9442. doi: 10.1039/c2ra21087h
   Web of Science ®Google Scholar
• Bi J, Lu Y, Dong Y, et al. Synthesis of folic acid-modified DOX@ ZIF-8 nanoparticles for targeted therapy of liver cancer. J Nanomater. 2018. 1357812. doi: 10.1155/2018/1357812
   Google Scholar
• Sandomierski M, Jakubowski M, Ratajczak M, et al. Zeolitic Imidazolate Framework‑8 (ZIF-8) modified titanium alloy for controlled release of drugs for osteoporosis. Sci Rep. 2022;12:9103. doi: 10.1038/s41598-022-13187-0
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Q, Liu R, et al. A versatile prodrug strategy to in situ encapsulate drugs in MOF nanocarriers: a case of cytarabine-IR820 prodrug encapsulated ZIF-8 toward chemo-photothermal therapy. Adv Funct Mater. 2018;28(35):1802830. doi: 10.1002/adfm.201802830
   Web of Science ®Google Scholar
• Qin Y-T, Peng H, He X-W, et al. Ph-responsive polymer-stabilized ZIF-8 nanocomposites for fluorescence and magnetic resonance dual-modal imaging-guided chemo-/photodynamic combinational cancer therapy. ACS Appl Mater Inter. 2019;11(37):34268–34281. doi: 10.1021/acsami.9b12641
   PubMed Web of Science ®Google Scholar
• Prabhu R, Anjali R, Archunan G, et al. Ecofriendly one pot fabrication of methyl gallate@ ZIF-L nanoscale hybrid as pH responsive drug delivery system for lung cancer therapy. Process Biochem. 2019;84:39–52. doi: 10.1016/j.procbio.2019.06.015
   Web of Science ®Google Scholar
• Fu X, Zhang G, Zhang Y, et al. Co-delivery of anticancer drugs and cell penetrating peptides for improved cancer therapy. Chin Chem Lett. 2021;32(4):1559–1562. doi: 10.1016/j.cclet.2020.10.011
   Web of Science ®Google Scholar
• Deng Q, Chen S, Fu C, et al. Long noncoding RNA expression profiles in sub-lethal heat-treated hepatoma carcinoma cells. World J Surg Oncol. 2017;15(1):1–14. doi: 10.1186/s12957-017-1194-4
   PubMedGoogle Scholar
• Zhang T, Wei Q, Zhou H, et al. Sustainable release of vancomycin from micro-arc oxidised 3D-printed porous Ti6Al4V for treating methicillin-resistant Staphylococcus aureus bone infection and enhancing osteogenesis in a rabbit tibia osteomyelitis model. Biomater Sci. 2020;8(11):3106–3115. doi: 10.1039/C9BM01968E
   PubMed Web of Science ®Google Scholar
• Mohamed Kasim MS, Sundar S, Rengan R. Synthesis and structure of new binuclear ruthenium(II) arene benzil bis(benzoylhydrazone) complexes: investigation on antiproliferative activity and apoptosis induction. Inorg Chem Front. 2018;5(3):585–596. doi: 10.1039/c7qi00761b
   Web of Science ®Google Scholar
• Mohamed Subarkhan MK, Ramesh R, Liu Y. Synthesis and molecular structure of arene ruthenium(II) benzhydrazone complexes: Impact of substitution at the chelating ligand and arene moiety on antiproliferative activity. New J Chem. 2016;40(11):9813–9823. doi: 10.1039/c6nj01936f
   Web of Science ®Google Scholar
• Mohan N, Mohamed Subarkhan MK, Ramesh R. Synthesis, antiproliferative activity and apoptosis-promoting effects of arene ruthenium(II) complexes with N, O chelating ligands. J Organomet Chem. 2018;859:124–131. doi: 10.1016/j.jorganchem.2018.01.022
   Web of Science ®Google Scholar
• Swaminathan S, Haribabu J, Mohamed Subarkhan MK, et al. Coordination behavior of acylthiourea ligands in their Ru(II)–benzene complexes─Structures and anticancer activity. Organometallics. 2022;41(13):1621–1630. doi: 10.1021/acs.organomet.2c00127
   Google Scholar
• Balaji S, Mohamed Subarkhan MK, Ramesh R, et al. Synthesis and structure of arene Ru(II) N∧O-chelating complexes: in Vitro cytotoxicity and cancer cell death mechanism. Organometallics. 2020;39(8):1366–1375. doi: 10.1021/acs.organomet.0c00092
   Web of Science ®Google Scholar
• Swaminathan S, Haribabu J, Mohamed Subarkhan MK, et al. Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(ii)-p-cymene complexes with acylthiourea ligands—in vitro and in vivo studies. Dalton Trans. 2021;50(44):16311–16325. doi: 10.1039/D1DT02611A
   PubMed Web of Science ®Google Scholar
• Wang Y, Jin J, Shu L, et al. New organometallic ruthenium(ii) compounds synergistically show cytotoxic, antimetastatic and antiangiogenic activities for the treatment of metastatic cancer. Chem Eur J. 2020;26(66):15170–15182. doi: 10.1002/chem.202002970
   PubMed Web of Science ®Google Scholar
• Pilliadugula R, Haribabu J, Mohamed Subarkhan MK, et al. Effect of morphology and (Sn, Cr) doping on in vitro antiproliferation properties of hydrothermally synthesized 1D GaOOH nanostructures. J Sci. 2021;6(3):351–363. doi: 10.1016/j.jsamd.2021.03.003
   Web of Science ®Google Scholar
• Giriraj K, Mohamed Kasim MS, Balasubramaniam K, et al. Various coordination modes of new coumarin Schiff bases toward Cobalt (III) ion: Synthesis, spectral characterization, in vitro cytotoxic activity, and investigation of apoptosis. Appl Organomet Chem. 2022;36(3):e6536. doi: 10.1002/aoc.6536
   Web of Science ®Google Scholar
• Sathiya Kamatchi T, Mohamed Subarkhan MK, Ramesh R, et al. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. Dalton Trans. 2020;49(32):11385–11395. doi: 10.1039/D0DT01476A
   PubMed Web of Science ®Google Scholar
• Mohamed Subarkhan MK, Ren L, Xie B, et al. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo. Eur J Med Chem. 2019;179:246–256. doi: 10.1016/j.ejmech.2019.06.061
   PubMed Web of Science ®Google Scholar
• Subarkhan MKM, Ramesh R. Ruthenium(ii) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity. Inorg Chem Front. 2016;3(10):1245–1255. doi: 10.1039/C6QI00197A
   Web of Science ®Google Scholar
• Zhong Z, Huang Y, Hu Q, et al. Elucidation of molecular pathways responsible for the accelerated wound healing induced by a novel fibrous chitin dressing. Biomater Sci. 2019;7(12):5247–5257. doi: 10.1039/C9BM00404A
   PubMed Web of Science ®Google Scholar
• Rangamuwa K, Leong T, Weeden C, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021;10(6):2842–2857. doi: 10.21037/tlcr-20-1075
   PubMed Web of Science ®Google Scholar
• Palussière J, Chomy F, Savina M, et al. Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg. 2018 91;13(1). doi: 10.1186/s13019-018-0773-y
   PubMedGoogle Scholar
• Löffler MW, Nussbaum B, Jäger G, et al. A non-interventional clinical trial assessing immune responses after radiofrequency ablation of liver metastases from colorectal cancer. Front Immunol. 2019;10:2526. https://www.frontiersin.org/article/10.3389/fimmu.2019.02526
   PubMed Web of Science ®Google Scholar
• Xu M, Hu Y, Ding W, et al. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials. 2020;258:120308. doi: 10.1016/j.biomaterials.2020.120308
   PubMed Web of Science ®Google Scholar
• Ojha T, Pathak V, Shi Y, et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Delivery Rev. 2017;119:44–60. doi: 10.1016/j.addr.2017.07.007
   PubMed Web of Science ®Google Scholar
• Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Delivery Rev. 2020;157:142–160. doi: 10.1016/j.addr.2020.06.005
   PubMed Web of Science ®Google Scholar
• Nijkamp MW, Van Der Bilt JDW, De Bruijn MT, et al. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg. 2009;249(5):814–823. doi: 10.1097/SLA.0b013e3181a38ef5
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi: 10.1038/s41580-018-0080-4
   PubMed Web of Science ®Google Scholar
• Hosui A, Kimura E, Abe S, et al. Long-term zinc supplementation improves liver function and decreases the risk of developing hepatocellular carcinoma. Nutrients. 2018;10(12):1955. doi: 10.3390/nu10121955
   PubMed Web of Science ®Google Scholar
• Xue Y, Yu B, Liu Y, et al. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial‐mesenchymal transition and inducing apoptosis. Prostate. 2019;79(6):647–656. doi: 10.1002/pros.23772
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang Y, Liu L, et al. One-pot synthesis of metal–organic frameworks with encapsulated target molecules and their applications for controlled drug delivery. J Am Chem Soc. 2016;138(3):962–968. doi: 10.1021/jacs.5b11720
   PubMed Web of Science ®Google Scholar
• Dumolard L, Ghelfi J, Roth G, et al. Percutaneous ablation-induced immunomodulation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(12):4398. doi: 10.3390/ijms21124398
   PubMed Web of Science ®Google Scholar
• Franklin RB, Levy BA, Zou J, et al. ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer. J Gastrointest Cancer. 2012;43(2):249–257. doi: 10.1007/s12029-011-9269-x
   PubMedGoogle Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;19914(3):199–208. doi: 10.1038/nrc3672
   Google Scholar